ReviewCurrent rheumatology reports2024
An Update on Kawasaki Disease.
Review in Current rheumatology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Association of the Aggregate Index of Systemic Inflammation with coronary artery aneurysm in Kawasaki disease patients.Pediatric research · 2026Article
- Biochemical outcomes and safety profiles of compound glycyrrhizin versus magnesium isoglycyrrhizinate in Kawasaki disease: a retrospective propensity score‑matched cohort study.Translational pediatrics · 2026Article
- Clinical correlation between platelet parameters and coronary artery lesions in pediatric Kawasaki disease.Frontiers in pediatrics · 2026Article
- Kawasaki disease shock syndrome with pulmonary involvement in a child: a case report.Frontiers in immunology · 2026Article
- Giant left main coronary artery aneurysm in a young adult female with suspected incomplete Kawasaki disease: a case report.Frontiers in medicine · 2026Article
- Single-cell multi-omics sequencing reveals the immunological disturbance underlying Kawasaki disease.Frontiers in molecular biosciences · 2026Article
- The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease.Frontiers in immunology · 2026Article
- Human pathological findings in Kawasaki disease: a narrative review of autopsy and biopsy evidence.Frontiers in immunology · 2026Review
- Epidemiological trends and healthcare burden of Kawasaki disease in children under 5 years in Taiwan.Scientific reports · 2025Article
- Plasma Exosomal-Derived SERPINA1 and GNAI2 Downregulation as Potential Diagnostic Biomarkers of Kawasaki Disease with Coronary Artery Aneurysms.International journal of molecular sciences · 2025Article
- Efficacy Analysis of a 12-Cytokine Panel for the Diagnosis of Kawasaki Disease and Prediction of Intravenous Immunoglobulin Resistance.Journal of inflammation research · 2025Article
- IL-10 and IL-2R as combined predictors of intravenous immunoglobulin resistance in Kawasaki disease: a retrospective cohort study.Frontiers in immunology · 2025Article
- Evaluating the quality and reliability of Kawasaki disease-related content on TikTok and Bilibili: a cross-sectional study.Frontiers in public health · 2025Article
- Age-Stratified Risk Factors for Coronary Thrombosis in Kawasaki Disease Patients with Medium-to-Large Coronary Artery Aneurysms.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo summarize advances in research on the epidemiology, pathogenesis, diagnosis, and treatment of Kawasaki Disease (KD), a systemic inflammatory illness of unknown etiology that affects children globally. RECENT
findingsThe epidemiology of KD was affected by the COVID-19 pandemic and advances in molecular immunology and machine learning have enabled research into its pathogenesis. There is ongoing research into agents that can be used to intensify initial treatment and accumulating evidence supporting the use of certain rescue regimens for refractory disease over others. There is promise surrounding a new coronary artery aneurysm prediction model. Research into the post-acute morbidity of KD continues. The COVID-19 pandemic temporarily reduced the incidence of KD. The NLRP3 inflammasome plays a key role in KD pathogenesis. Intensified initial treatment benefits high-risk patients, yet no intensification regimen shows superiority over another. Corticosteroids, infliximab, or combination therapy with IVIg plus another agent may be superior rescue regimens compared to IVIg alone for refractory KD. The Son score, developed in North America, predicted coronary artery lesions in Japanese and Italian cohorts. Patients with a history of KD may carry long-term physical and emotional burdens that persist into adulthood yet appear to have typical neurocognitive development. Successful transition to adult healthcare presents a challenge.
Indexed as
Identifiers
39625646What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.